Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Brand Name :
Zarontin
Synonyms :
Class :
Anticonvulsants; Succinimide
Dosage forms & Strengths:Â
Adult:Â
Capsule:Â
250 mgÂ
Syrup:Â
250 mg/5mlÂ
spironolactone and hydrochlorothiazide
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ethosuximide
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
it may diminish the metabolism when combined with diosmin
When ethosuximide is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When ethosuximide is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when ethosuximide is used together with fencamfamin
When ethosuximide is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When ethosuximide is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When ethosuximide is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
the effect of ethosuximide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may alter the level by affecting CYP450 enzyme metabolism
may alter the level by affecting CYP450 enzyme metabolism
Frequency undefined:Â
DizzinessÂ
HeadacheÂ
SomnolenceÂ
AnorexiaÂ
DiarrheaÂ
Gastrointestinal upsetÂ
NauseaÂ
VomitingÂ
Ethosuximide is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
The benefits of taking the drug in pregnant women should outweigh the risks to the fetus.Â
Breastfeeding warnings:Â Â
Take the drug with caution during breastfeeding. Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name:Â ethosuximideÂ
Pronounced: per-am-pa-nelÂ
Why do we use ethosuximide?Â
Ethosuximide is an anticonvulsant agent that treats seizures.Â